|
Indications and Dosage
Oral
Allergic conditions Adult: 1 mg bid increased to 2 mg bid if needed.
Child: 6-12 yr: 0.5-1 mg bid. |
|
Administration
May be taken with or without food. May be taken w/ food or milk if stomach upset occurs.
|
|
Contraindications
Neonates; patients receiving MAOI therapy; lactation.
|
|
Special Precautions
Angle-closure glaucoma, increased intraocular pressure, stenosing peptic ulcer, pyloroduodenal obstruction, epilepsy; renal and hepatic impairment. May impair ability to drive or operate machinery; pregnancy.
|
|
Adverse Reactions
Drowsiness, dizziness, headache, fatigue, nervousness; anticholinergic effects, thick bronchial secretions; arthralgia; pharyngitis; increased appetite, wt gain, nausea, diarrhoea, abdominal pain, dry mouth; impaired alertness.
|
|
Drug Interactions
Potentiates CNS depression with other CNS depressants e.g. TCAs, procarbazine and alcohol.
Potentially Fatal: MAOIs enhance anticholinergic side effect of azatadine. Enhance depressant action of anxiolytic and sedating drugs. |
|
Food Interaction
Alcohol may enhance sedative effects.
|
|
Action
Description:
Mechanism of Action: Azatadine has anticholinergic and antiserotonin activity. It inhibits mediator release from mast cells by preventing calcium entry through voltage-dependent calcium channels. Pharmacokinetics: Absorption: Absorbed from the GI tract (oral); peak plasma concentrations after 4 hr. Metabolism: Minimal metabolism. Excretion: Via the urine (as unchanged drug and metabolites); 9-12 hr (elimination half-life). |
|
Storage
Store at 2-30°C.
|
|
MIMS Class
|
Sign Out
